Clinical trials
Advanced Solid Tumor Cancer clinical trials
Below are recruiting advanced solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,352 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06298058RecruitingPhase 1
SIBP-A13 injection for advanced solid tumors
This trial tests a new drug called SIBP-A13 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for different cancer types, including lung, breast, and head and neck cancers.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06960395RecruitingPhase 1
Study of VIR-5525 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug called VIR-5525, either alone or combined with pembrolizumab (an immunotherapy), for people with advanced solid tumors that have not responded to other treatments or cannot undergo standard therapy. It focuses on certain cancer types and tumors with a specific genetic change (EGFR amplification).
Scottsdale, ArizonaAges 18 years+ - NCT06514651RecruitingPhase 1
MAQ-001 for advanced solid tumors after PD-1/PD-L1 therapy
This study tests a new experimental drug called MAQ-001 in people with advanced solid tumors or lymphomas that have already been treated with a PD-1/PD-L1 checkpoint inhibitor. The goal is to see if MAQ-001 can shrink or control the cancer when other treatments are no longer working.
LyonAges 18 years+ - NCT07265921RecruitingPhase 1
Study of SIM0609 for advanced solid tumors
This trial tests an investigational new drug, SIM0609, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see early signs that it might help slow or shrink tumors.
BeijingAges 18 years+ - NCT06885281RecruitingPhase 1/Phase 2
Study of ZL-1310 for neuroendocrine carcinoma
This trial is testing an experimental drug called ZL-1310 for people with neuroendocrine carcinoma (a rare, fast-growing cancer) that has spread or can't be removed. It aims to see if the drug is safe and works against the cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06384807RecruitingPhase 1/Phase 2
Study of BHV-1510 for advanced solid tumors
This trial tests a new drug, BHV-1510, alone or combined with another drug (cemiplimab), for people with advanced solid tumors that haven't responded to other treatments. It's for those who are still in fairly good health and have not had certain prior treatments.
Duarte, CaliforniaAges 18 years+ - NCT07260708RecruitingPhase 1
Testing TQB2922 injection for advanced lung cancer
This trial tests a new injection called TQB2922 for people with advanced non-squamous non-small cell lung cancer who have already tried standard treatments. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
Guangzhou, GuangdongAges 18–75 - NCT05684965RecruitingPhase 1/Phase 2
Study drug for advanced solid cancers after standard treatments
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
Sacramento, CaliforniaAges 18 years+ - NCT06764836RecruitingPhase 1
IMM2510 + IMM27M for advanced solid tumors
This study tests a combination of two immune-based drugs, IMM2510 and IMM27M, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07242417RecruitingEarly Phase 1
TC-G203 for adults with GPC3-positive advanced solid tumors
This trial tests an experimental cell therapy (TC-G203) for people with advanced solid tumors that have a specific protein called GPC3. It aims to see if this treatment is safe and effective for those who haven't responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07274085RecruitingPhase 1
Study of HDM2017 for advanced solid tumors
This trial tests a new drug called HDM2017 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07223125RecruitingPhase 1
Study of JNJ-89862175 for Advanced Solid Tumors
This trial tests a new drug called JNJ-89862175 for people with certain advanced solid tumors, including lung adenocarcinoma, kidney cancer, ovarian cancer, and uterine cancer. The goal is to see if this treatment is safe and effective.
Orlando, FloridaAges 18 years+ - NCT06532565RecruitingPhase 1
Study of GS-2121 alone or with other drugs for advanced solid tumors
This trial tests a new drug, GS-2121, given alone or with other therapies, for adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Palo Alto, CaliforniaAges 18 years+ - NCT05881525RecruitingPhase 1
Testing NY-ESO-1 T-cell therapy for advanced solid tumors
This Phase 1 study tests a personalized immune therapy made from T cells to treat advanced solid cancers that carry a marker called NY-ESO-1. You may be able to join if your tumor shows the right NY-ESO-1 level and your body and lab tests can safely handle treatment.
ChongqingAges 18–70 - NCT06096974RecruitingPhase 1
Study of YL-17231 for advanced solid tumors with RAS mutations
This trial tests a new drug called YL-17231 in people with advanced solid tumors that have specific changes (mutations) in the KRAS, HRAS, or NRAS genes. It is for patients whose cancer has stopped responding to or cannot tolerate standard treatments.
Cincinnati, OhioAges 18 years+ - NCT05661201RecruitingPhase 1
Testing a KRAS drug and doxorubicin for certain solid tumors
This Phase 1 study tests a drug called NEROFE together with doxorubicin in people whose tumors have a specific KRAS mutation and show ST2 in tumor tissue. It’s meant to find the safest dose and whether the treatment can shrink or control these advanced cancers.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07256756RecruitingPhase 1
A study of GC203 TIL for advanced solid tumors
This trial tests a new treatment called GC203 TIL, which uses your own immune cells to fight advanced solid tumors. It's for people who have tried standard treatments and have a tumor that can be removed to create this therapy.
ShenzhenAges 18–75 - NCT06541639RecruitingPhase 1
Immune cell therapy for advanced solid tumors
This study tests a new immune cell therapy (EVM16) given alone or with another drug (tislelizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07258121RecruitingPhase 1/Phase 2
ZGGS34 for Advanced Solid Tumors Targeting MUC17
This trial tests an experimental drug called ZGGS34 that targets a protein (MUC17) found on some cancer cells. It is designed for people with advanced solid tumors (stomach, pancreas, colorectal, or other) that have not responded to standard treatments.
Zhengzhou, HenanAges 18–75 - NCT06659341RecruitingPhase 1
Study of BAY3498264 with Sotorasib for KRAS G12C Cancers
This trial tests a new drug (BAY3498264) combined with sotorasib, a targeted therapy, for people with advanced cancers that have a specific genetic change called KRAS G12C. It's for those who have already tried other treatments and need new options.
Albury, New South WalesAges 18 years+ - NCT07252414RecruitingPhase 1
Study of GenSci143 for advanced solid tumors
This trial tests a new drug, GenSci143, for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has spread or come back and you have no other standard options left.
Zhengzhou, HenanAges 18 years+ - NCT05868174RecruitingPhase 1
Testing a targeted radiation drug plus a DNA repair blocker
This early-phase trial tests whether combining a targeted radiation medicine (177Lu-TLX250) with a DNA repair–blocking drug (peposertib) can shrink advanced solid tumors. It is designed for tumors that strongly show a marker called CAIX, which helps the radiation home in and may make treatment more effective.
North Ryde, New South WalesAges 18 years+ - NCT07252479RecruitingPhase 1
Testing a new RAS inhibitor for advanced solid tumors
This trial is testing a new oral medication (AN9025) for people with advanced solid tumors that have a RAS mutation, such as pancreatic, colorectal, lung, or melanoma. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working.
Orlando, FloridaAges 18 years+ - NCT06796699RecruitingPhase 1
GH56 capsule study for MTAP-deleted advanced solid tumors
This study tests an experimental capsule (GH56) for people whose advanced solid tumors have a specific genetic change called MTAP deletion. The goal is to see if the capsule is safe and helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Advanced Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor cancer?
- Yes. Clin2 currently lists 1,352 recruiting advanced solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.